We have identified, purified, and determined the complete amino acid sequence of a novel protein, ohanin from Ophiophagus hannah (king cobra) venom. It is a small protein containing 107 amino acid residues with a molecular mass of 11951.47 ؎ 0.67 Da as assessed by electrospray ionization-mass spectrometry. It does not show similarity to any known families of snake venom proteins and hence is the first member of a new family of snake venom proteins. It shows similarity to PRY and SPRY domain proteins. It is nontoxic up to 10 mg/kg when injected intraperitoneally in mice. Ohanin produced statistically significant and dose-dependent hypolocomotion in mice. In a pain threshold assay, it showed dose-dependent hyperalgesic effect. The ability of the protein to elicit a response at greatly reduced doses when injected intracerebroventricularly as compared with intraperitoneal administration in both the locomotion and hot plate experiments strongly suggests that ohanin acts on the central nervous system. Since the natural abundance of the protein in the venom is low (ϳ1 mg/g), a synthetic gene was constructed and expressed. The recombinant protein, which was obtained in the insoluble fraction in Escherichia coli, was purified under denaturing condition and was refolded. Recombinant ohanin is structurally and functionally similar to native protein as determined by circular dichroism and hot plate assay, suggesting that it will be useful in future structure-function relationship studies.
Snake venoms are complex mixtures of bioactive compounds, including enzymatic and non-enzymatic proteins, as well as low molecular weight components including peptides, lipids, nucleotides, carbohydrates, and amines (1, 2). Venom proteins generally play a number of roles, such as immobilizing, paralyzing, killing, and digesting prey (3). Hence, snake venoms serve both offensive and defensive purposes (4) . Over the past 40 years, a plethora of toxin proteins have been isolated and characterized from venoms of snakes (5) .
These toxin proteins, however, belong to a very small number of structural superfamilies of proteins (6) . The members of a superfamily share similar molecular scaffold, but at times, exhibit distinct biological functions.
The major enzyme groups found in snake venoms include phospholipases, serine proteinases, metalloproteinases, phosphodiesterases, acetylcholinesterase, L-amino acid oxidases, and nucleases (2, 7). Generally, enzymes in the venom have molecular masses ranging from 13,000 to 150,000 Da. Most of these are hydrolases and possess a digestive role. On the other hand, over 1,000 non-enzymatic venom proteins have been characterized, and they are grouped into three-finger toxins, serine proteinase inhibitors, lectins, sarafatoxins, nerve growth factors, atrial natriuretic peptides, bradykinin-potentiating peptides, helveprins/CRISP proteins, disintegrins, and waprins (6 -9) . Non-enzymatic polypeptide toxins have molecular masses around 1,000 to 25,000 Da and are rich in disulfide bonds. Therefore, they are robust and are relatively stable once isolated. The low molecular mass compounds have molecular masses of less than 1,500 Da. They are less active biologically and are presumed to be enzyme cofactors (2).
So far, snake venom proteins that are found in abundance or that are highly toxic have been isolated and characterized. With the advent of new and more sensitive methods, we are able to characterize proteins that are found in smaller quantities. We are interested in the study of novel protein components from snake venoms (7) . In this report, we describe the identification, purification and functional characterization of the first member of a new family of snake venom proteins, ohanin from king cobra venom. It induces hypolocomotion and hyperalgesia in experimental mice. The action of ohanin appears to be mediated by central nervous system as it was 6,500-fold more potent when administered i.c.v. than intraperitoneal. Recombinant ohanin was successfully expressed in Escherichia coli for future cassette-based mutagenesis and structure-function relationship studies. This is the first snake venom protein reported so far which induces hypolocomotion and hyperalgesia in experimental mice. An understanding of its physiological role(s) and mechanism of action(s) is useful in the development of prototypes of new pharmaceutical agents or as research tools.
EXPERIMENTAL PROCEDURES
Materials-Lyophilized king cobra crude venom was obtained from PT Venom Indo Persada (Jakarta, Indonesia). All chemicals were purchased from Sigma with the exception of the following: Lys-C endopeptidase and trypsin were purchased from Wako Pure Chemicals (Osaka, Japan), reagents for Edman degradation N-terminal sequencing (Applied Biosystems, Foster City, CA), acetonitrile (Merck KGaA, Darmstadt, Germany), Luria Bertani broth and agar were purchased from Q.BIOgene (Irvine, CA) and SDS-PAGE gel standards (prestained broad range SDS-PAGE standards and Precision plus prestained dual-color standard) were purchased from Bio-Rad. Superdex 30 Hiload (16/60) and RPC C2/C18 (10 , 120 Å, 2.1 mm ϫ 100 mm) columns were obtained from Amersham Biosciences. RPJupiter C18 (5 , 300 Å, 1 mm ϫ 150 mm) and RP-Jupiter C18 (10 , 300 Å, 10 mm ϫ 250 mm) columns were purchased from Phenomenex (Torrance, CA). Nickel-NTA agarose was purchased from Qiagen GmbH (Hilden, Germany). All the oligonucleotides were purchased from BioBasic (Shanghai, China). Platinum Taq polymerase, dNTP mix and ladders (50 bp, 100 bp, and 1 kb Plus) were purchased from Invitrogen. All restriction endonucleases used were obtained from New England Biolabs (Beverly, MA) and pGEMT-easy vector was obtained from Promega. Water was purified with a MilliQ system (Millipore, Billerica, MA).
Animals-Swiss albino male mice (20 Ϯ 2 g) were used for the animal experiments. In order to reduce the impact caused by environmental changes and handling during behavioral studies, mice were acclimatized to the Laboratory Animal Holding Center and laboratory surroundings for 3 days and at least 1 h prior to experiments, respectively. Animals were kept under standard conditions with food (low protein diet) and water available ad lib. The animals were housed 4 per cage in a light-controlled room (12 h light/dark cycle, light on 07:00 h) at 23°C and 60% relative humidity. All behavioral experiments were performed between 08:30 and 13:00 h. Each test group consisted of at least 7 mice, and each mouse was used only once. All animal experiments were conducted according to guidelines set by the Laboratory Animal Holding Center of the National University of Singapore (adapted from Howard-Jones, Ref. 10) .
Liquid Chromatography-Mass Spectrometry (LC/MS) 1 of King Cobra Venom-Lyophilized crude venom (60 g) was dissolved in 20 l of MilliQ water before loading via direct injection onto an RP-Jupiter C18 analytical column equilibrated with 0.1% (v/v) trifluoroacetic acid attached to a PerkinElmer Sciex API300 LC/MS/MS system mass spectrometer (Thornton, Canada). The crude mixture was eluted using a linear gradient of 80% (v/v) acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 50 l/min. Electrospray ionization mass spectrum was acquired in positive ion mode with an orifice potential of 80 V. Nitrogen was used as curtain gas with a flow rate of 0.6 liters/min and as nebulizer gas with a pressure setting of 100 psi. Full scan data were acquired over the ion range from 500 to 3000 m/z with step size of 0.1 Da. Data processing was performed with the aid of BioMultiview software (PerkinElmer Sciex, Thornton, Canada).
Isolation and Purification-Lyophilized crude venom (several batches of 200 mg each) was dissolved in 2 ml of MilliQ water and loaded onto a Superdex 30 column pre-equilibrated with 50 mM of Tris-HCl (pH 7.4). The proteins were eluted with 50 mM of Tris-HCl (pH 7.4) at a flow rate of 1 ml/min on a Fast Protein Liquid Chromatography system (FPLC) (Amersham Biosciences). Protein elution was monitored at 280 nm. The fraction of interest was then loaded onto an RP-Jupiter C18 semi-preparative column equilibrated with 0.1% trifluoroacetic acid (v/v) on Vision Work station (PE Applied Biosystems, Foster City, CA). The bound proteins were eluted using a linear gradient of 80% acetonitrile in 0.1% trifluoroacetic acid (v/v) at a flow rate of 2 ml/min over an hour. Protein elution was monitored at 280 and 215 nm. The protein of interest was identified by mass determination (described below).
Reduction and Pyridylethylation-Lyophilized and purified protein of interest was reduced and pyridylethylated using the procedure described earlier (11) . Protein (500 g) was dissolved in 500 l of denaturant buffer (6 M guanidine hydrochloride (GdnCl), 50 mM Tris-HCl, 1 mM EDTA, pH 8.0). After the addition of 10 l of ␤-mercaptoethanol, the mixture was incubated at 37°C for 2 h under vacuum. Subsequently, 20 l of 4-vinyl pyridine was added to the mixture and kept at room temperature (ϳ25°C) for another 2 h under vacuum. The reduced and pyridylethylated protein was loaded onto an RP-RPC C2/C18 analytical column equilibrated with 0.1% trifluoroacetic acid (v/v) on a SMART Workstation (Amersham Biosciences). The bound proteins were eluted using a linear gradient of 80% acetonitrile in 0.1% trifluoroacetic acid (v/v) at a flow rate of 200 l/min over an hour. Protein elution was monitored at 280 and 215 nm.
Enzymatic Cleavage-Digestion of pyridylethylated protein with Lys-C endopeptidase and trypsin were performed at 37°C for 20 h. Protein (150 g) was dissolved in 150 l of enzymatic digestion buffer (50 mM Tris-HCl, 4 M urea, 5 mM EDTA, pH 7.5), and proteases were added at a ratio of 1:50 (w/w).
Chemical Cleavage-Digestion of reduced and pyridylethylated protein with formic acid (Asp-specific) was performed as described by Inglis (12) . Briefly, 150 g of pyridylethylated protein was dissolved in 2% of formic acid in a glass vial and then frozen at Ϫ30°C. Subsequently, under vacuum, the vial was thawed at room temperature and then sealed off. The vial was then heated at 108°C for 2 h and allowed to cool to room temperature.
Separation of Digested Peptides-The peptides generated by both the enzymatic and chemical digestions were fractionated using RP-RPC C2/C18 analytical column on a SMART Workstation using a linear gradient of 80% acetonitrile in 0.1% of trifluoroacetic acid (v/v) over an hour. The elution of peptides was monitored at 215 and 280 nm.
Molecular Mass Determination-ESI/MS was used to determine the precise masses and purity (Ϯ 0.01%) of both the native protein and peptides. The RP-HPLC fractions were directly injected into the API300 LC/MS/MS system mass spectrometer. Ionspray, orifice, and ring voltages were set at 4,600 V, 50 V, and 350 V, respectively. Nitrogen was used as curtain gas with a flow rate of 0.6 liters/min and as nebulizer gas with a pressure setting of 100 psi. The mass was determined by direct injection at a flow rate of 50 l/min using the LC-10AD Shimadzu Liquid Chromatography pump as solvent delivery system (40% acetonitrile in 0.1% trifluoroacetic acid). BioMultiview software was used to analyze and deconvolute the raw mass spectrum.
N-terminal Sequencing-N-terminal sequencing of the native and digested peptides were performed by automated Edman degradation using a PerkinElmer Applied Biosystems 494 pulsed-liquid phase protein sequencer (Procise) with an on-line 785A PTH-derivative amino acid analyzer. The PTH-derivative amino acids were then sequentially identified by mapping the respective separation profiles with the standard chromatogram.
Methods for Protein Administration-The volume injected via intraperitoneal route was 200 l, and the protein was dissolved in water. The intracerebroventricular (i.c.v.) injection was made in a volume of 2 l through a puncture point at 1.5-mm lateral and 1.0-mm posterior to bregma using a 10 l of luer-tip Hamilton microsyringe with a modified needle so as to penetrate 2 mm from the top of the skull (13) . The protein for i.c.v. injection was dissolved in artificial cerebrospinal fluid. The needle was rotated on withdrawal. These two administration methods were used for the locomotor activity and hot plate experiments.
In Vivo Toxicity Test-Native protein was injected intraperitoneal into the mice at doses of 0.1 mg/kg, 1 mg/kg, and 10 mg/kg (n ϭ 2). After injection, behavioral observations on the mice were recorded every 15 min for up to 6 h. Animals were sacrificed after 24 h, and postmortem examination was performed.
Locomotor Activity-Locomotor activity of the mice was measured by an NS-AS01 activity monitoring system (Neuroscience, Inc., Tokyo, Japan), which is composed of an infrared ray sensor, a signal amplification circuit and a control circuit. Movement of the mice was detected by the infrared ray sensor on the basis of released infrared rays associated with their temperature. Each mouse was removed from its home cage and housed individually in a cage (12 cm ϫ 12 cm ϫ 30 cm) with an 8-channel infrared ray sensors placed over the cages. The cage contained ϳ40 ml of sawdust on the floor. Motor activity of eight animals kept in separate cages was measured simultaneously. All movements of a distance of 4 cm or more were detected by the infrared ray sensors and each represented a measure of general mobility of the injected mice. The activity of the animals was assessed by performing a prerun experiment. Animals used for the subsequent experiment had a minimum of 450 counts and a maximum of 850 counts over the first 20 min of the prerun experiment. Active mice were then administered with the protein and placed in the same motor activity monitoring system. Immediately after this, counts of locomotor activity were collected in 10-min intervals for 80 min with a computer-linked analyzing system (AB System-24A, Neuroscience, Inc., Tokyo, Japan).
Hot Plate Assay-Each mouse was placed on a hot plate (55°C) and confined using a transparent plastic ring (diameter 12 cm, height 13 cm). The hot plate apparatus was a sealed wooden box with smooth metal surface 15 cm ϫ 15 cm and was heated using a water bath (Model Y22 Grant, Cambridge, UK). The latency time was measured from the time the mouse was gently introduced onto the hot plate to the time when it first showed one of the following responses: jumping, licking, or stamping of a limb, as described by Woolfe and MacDonald (14) . The hot plate assay was carried out 15 min after drug administration by intraperitoneal or i.c.v. routes.
Analysis of Results and Statistics-Changes in locomotor activity were analyzed by two-way ANOVA with repeated measures. Hyperalgesic effect induced by ohanin was analyzed using one-way ANOVA. All ANOVAs were followed by post-hoc analysis with Bonferroni correction. Statistical significance was indicated when p Ͻ 0.05.
Design, Assembly, and Cloning of the Synthetic Gene-The fulllength synthetic gene comprising of 369 bp was assembled from two fragments, and each fragment was constructed from two overlapping oligonucleotides, ranging from 96 bp to 117 bp, respectively, with an overlapping region of 21 bp enriched with more than 50% GC content to promote specific annealing. Primer 1 (5Ј-GGAATTCGTCGACGGATC-CATGCTAGCCC GCCGGGTAACTGGCAGAAAGCGGACGTCACCTT-CGATAGCAACACCGCGTTCGAAAGCCTGGTGGTGAGCCCGGAC-3Ј) and primer 2 (5Ј-TCC CCCCGGGCTGCCTAGGACGCACGGGCTC-GAGGAGAAGCGTTCCGGGCTATCCGGCACACCTTTCGGCACACC-AACGTTTTCCACGGTTTTTTTGTCCGGGCTCACCACCAGGCT-3Ј) were used to prepare the first fragment; primer 3 (5Ј-TCCCCCCGGG-TTTCCGTTCCGGAAAACACTTCTTCGAGGTGAAATACGGTACCCA-GCGTGAATGGGCGGTGGGGCTAGCGGGTAAAAGCGTGAAGCGT-AAGGGTTAC-3Ј) and primer 4 (5Ј-GACTAGTAAGCTTGCGGCCGCC-TACAGCCACCACAGACCTTTCTGCCAGATACGTTCTTCCGCACCA-GCCTTAAGTAACCCTTACGCTTCACGCT-3Ј) were used to prepare the second fragment. (Nucleotides in the above sequences underlined were the flanking sequences for XmaI restriction site.) PCR mixture to generate both the fragments contained a final concentration of 0.3 units of Platinum Taq polymerase, 0.2 mM dNTP mix, and 0.2 M primers in a total volume of 25 l. The amplification condition was as follows: 1 cycle of 94°C/1 min; 20 cycles of 94°C/30 s, 55°C/30 s, 72°C/1 min; and a final extension of 72°C/5 min. The two fragments were digested with XmaI and ligated together to obtain the full-length synthetic gene. This ligation product was cloned into pGEMT-easy vector and sequenced.
Expression of Recombinant Ohanin-The 369-bp synthetic gene fragment was double-digested by restriction endonucleases BamHI and NotI for cloning into the expression vector. VectorM (a modified version of pET32A) was used to express the synthetic ohanin in E. coli BL21/ DE3 strain. The subcloning resulted in an expression of fusion protein consisting of hexahistidine tag at the N-terminal. For expression, a single colony harboring vectorM/ohanin, was inoculated into LB medium containing 100 g/ml of ampicillin (Amp) incubated at 37°C and 200 rpm for 14 h. The overnight culture was inoculated into fresh LB medium containing 100 g/ml of Amp at 1:50 dilution. Again, the bacterial culture was incubated at 37°C and 200 rpm until the culture reached an A 600 of ϳ0.6. Isopropyl-␤-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 0.1 mM to induce the expression and was further incubated at 16°C and 200 rpm for 16 h before the bacteria were harvested. Bacterial cells were stored at Ϫ80°C until used. The expression of recombinant protein in E. coli was analyzed by SDS-PAGE according to the method of Laemmli (15) using 15% polyacrylamide gel.
The cells expressing the His-tagged fusion protein were thawed for 15 min and lysed using a final concentration of 0.5 mg/ml lysozyme at 4°C for 15 min followed by mild sonication (six 1-min bursts) with adequate cooling in lysis buffer (10 mM Tris-HCl, 5 mM ␤-mercaptoethanol, pH 8.0). After centrifugation at 16,000 rpm, the pellet containing the inclusion bodies and cell debris was collected and resuspended in binding buffer under denaturing conditions (6 M GdnCl, 10 mM TrisHCl, 5 mM ␤-mercaptoethanol, pH 8.0).
Purification, Refolding, and Cleavage of the Fusion Protein-The process of dissolution of the pellet was allowed to continue for at least 4 h at 4°C using binding buffer under denaturing conditions. Cell debris that could not be dissolved by binding buffer was removed by centrifugation. The supernatant was loaded into a charged Ni-NTA resin column pre-equilibrated with binding buffer. Affinity chromatography was carried out according to manufacturer's guidelines. After washing extensively using wash buffer (10 mM imidazole (IMD), 6 M GdnCl, 10 mM Tris-HCl, 5 mM ␤-mercaptoethanol, pH 8.0), the bound protein was eluted using minimum volume of elution buffer (250 mM IMD, 6 M GdnCl, 10 mM Tris-HCl, 5 mM ␤-mercaptoethanol, pH 8.0). Elution and concentration of the fusion protein was monitored at 280 nm.
All the following refolding steps were carried out at 4°C. First, the concentration of the denatured fusion protein was adjusted using the elution buffer to ϳ6 mg/ml monitored at 280 nm. Then, 15 mg of the denatured fusion protein (2.5 ml) was diluted slowly in MilliQ water with 5 mM ␤-ME. MilliQ water containing 5 mM ␤-ME was delivered using a peristaltic pump (Amersham Biosciences) at a flow rate of 50 l/min into the beaker containing the denatured fusion protein with vigorous stirring until the concentration of GdnCl slowly decreased to 1 M. The diluted unfolded fusion protein was dialyzed for 36 h against 200-fold excess MilliQ water containing 5 mM ␤-mercaptoethanol, which was changed every 12 h.
Lyophilized refolded fusion protein (1 mg/ml) was dissolved in 0.1 M HCl. The solution was flushed with N 2 for 3 min prior to the addition of 100:1 molar excess of cyanogen bromide (CNBr) with respect to the Met content. Solutions of CNBr were prepared fresh prior to experiment by dissolving the appropriate amount of solid in 100% acetonitrile to a final concentration of 100 mg/ml. The reaction mixture was incubated at room temperature under darkness for 24 h before subjecting it to RP-HLPC for purification.
Measurement of Circular Dichroism (CD) Spectra-The secondary structures of native and recombinant ohanin were measured by recording far-UV CD spectra on a Jasco J810 spectropolarimeter (Jasco Corporation, Tokyo, Japan) with a 2 mm path-length cell over a wavelength range of 260 to 190 nm at 22°C. The cuvette chamber was continuously purged with nitrogen before and during the experiments. Measurements for both the native and recombinant protein were made in MilliQ water and average of three scans taken to obtain a good signal to noise ratio. The results were expressed as the mean residue ellipticity ()in deg⅐cm 2 ⅐dmol Ϫ1 . The ␣-helix, ␤-sheet, and random coil contents were estimated using the method described at www.embl-heidelberg.de/ ϳandrade/k2d/.
RESULTS

Identification of Novel Protein from King Cobra Venom-
Crude venom from Ophiophagus hannah (king cobra) was profiled using LC/MS (Fig. 1) to identify new and interesting protein components in the venom. Peptides and proteins detected by LC/MS were organized by retention time (Table I) . Proteins eluted after 50 min gave a relatively noisy m/z spectra and hence their molecular masses were not determined. This could be because of the large size of the proteins as well as the glycosylation and other post-translational modifications. Thus, mass profiling of king cobra venom using LC/MS demonstrates a limitation of this technique. With the LC/MS profile, we first searched for proteins with masses that are distinct from that of the well-established toxin families. We identified a protein with a molecular mass of 11951.35 Ϯ 3.92 Da, which was different from any of the established families and hence we decided to carry out further studies on this novel protein.
Isolation and Purification of the Novel Protein-The novel protein was purified from king cobra venom via a two-step purification procedure. The first step involved the separation of the crude venom using gel filtration chromatography. Because the molecular mass of the novel protein was ϳ12 kDa, Superdex 30 (Hiload 16/60) column was selected for gel filtration chromatography. Gel filtration of crude venom yielded six major peaks ( Fig. 2A) . We subjected the first three peaks: peak 1a, 1b, and 2, from gel filtration chromatography to RP-HPLC. Individual fractions from RP-HPLC were assessed using ESI/MS (data not shown). The protein fraction, which eluted at a gradient of 38 -40% buffer B (80% acetonitrile in 0.1% trifluoroacetic acid) from peak 1b of gel filtration (Fig. 2B) , was found to be homogenous with a molecular mass of 11,951.47 Ϯ 0.67 Da (Fig. 2C) . The overall yield of the novel protein was ϳ1 mg from 1 g of crude venom.
Determination of the Amino Acid Sequence-N-terminal sequencing of the native protein was determined by Edman degradation and it resulted in the identification of the first 40 residues. The N-terminal sequence showed no sequence homology to any of the proteins from known snake toxin families. To complete the sequence, pyridylethylated protein was digested with Lys-C endopeptidase, trypsin, and formic acid. Peptides from the respective digests were separated by reverse phase HPLC (data not shown). Molecular mass and the N-terminal sequences of the purified peptides were obtained to complete the full-length amino acid sequence (Fig. 3A) . The sequences of peptides and the entire protein were verified by comparing the calculated and observed masses of the digested peptides (Table II) . The observed molec- ular masses matched well with the calculated molecular masses. The novel protein contains 107 amino acid residues with one free cysteine and no post-translational modifications. We named this novel protein ohanin because it was purified from the venom of king cobra O. hannah.
Sequence Analyses of Ohanin-Comparison of the full-length amino acid sequence of ohanin with those of other proteins using the BLASTP algorithm (www.ncbi.nlm.nih.gov/BLAST/) (16) showed 93% sequence identity with Thai cobrin (SP: P82885) isolated from monocled cobra (Naja kaouthia). Although its sequence was deposited in the protein data base, there is no published literature on Thai cobrin. Thus, ohanin and Thai cobrin form the first members of a new family of snake toxins. Other than with Thai cobrin, ohanin did not display significant sequence similarity (E-values Ͼ10 Ϫ5 ) with other proteins in the GenBank TM data base. As a second step, conserved protein domain data base (CDD) (www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) (17) was used to search for conserved domains to predict the biological function of ohanin, based on the assumption that domains are the fundamental units of protein structure and function (18) . Residues 9 -107 of ohanin displayed an overall identity of 44% and similarity of 54% to the truncated PRY-SPRY domains (Fig.  3B) . PRY is a domain, which is present in tandem with SPRY domain (see "Discussion" for details). The SPRY domain has been identified as a subdomain within the B30.2-like domain (19) . SPRY domains and B30.2-like domain are found in a variety of proteins (see Henry et al. (20, 21) 
for details).
In Vivo Toxicity Test-Ohanin was used for in vivo toxicity study in mice. All mice were observed to be active prior to the start of the experiment. Upon intraperitoneal injection of the protein, mice with doses of 1 mg/kg and 10 mg/kg became quiet and sluggish in movement. However, they recovered 2 h after the injection with no obvious signs of paralysis of the limbs and the respiratory system. None of the mice died even at doses of 10 mg/kg. Analysis of gross pathology 24 h after the injection showed no signs of hemorrhage or necrosis in the brain, heart, lungs, kidneys, spleen, and liver as compared with those from the control animals (data not shown).
Locomotor Activity-To quantitatively verify our observations from the in vivo toxicity test, effects of ohanin on the locomotor activity of the injected mice were examined. As shown in Fig. 4A , ohanin at doses of 0.1 mg/kg, 1 mg/kg, and 10 mg/kg induced dose-dependent hypolocomotion after intraperitoneal injection (F 3,30 ϭ 5.787, p Ͻ 0.01). The decrease in the locomotor activity was statistically significant between 10 mg/kg dose and the 0.1 mg/kg dose (p ϭ 0.030); between 10 mg/kg dose and the control (p ϭ 0.004) as shown in Fig. 4A . At 10 mg/kg dose the total movement counts decreased to 742 Ϯ 190 compared with the controls (1942 Ϯ 147). The dose-dependent inhibition was different even at 10 min after injection as shown in Fig. 4B . There was no statistically significant time effect within the same dose for the whole experimental duration of 1 h as indicated by two-way repeated measures ANOVA, suggesting that the inhibition effect was not yet recovered. The effect beyond the experimental duration (1 h) was not determined. Prolonged physical activity and lack of food might exhaust the mice. Hence, the resulting sluggishness beyond the experimental duration may not be representative of the protein effects alone.
Intracerebroventricular injection was used to assess the direct effect of ohanin on the central nervous system. The dosages used for i.c.v. were ϳ1,000-fold less than that given for intraperitoneal of the high, intermediate, and low doses. Ohanin showed statistically significant (F 3,26 ϭ 9.112, p Ͻ 0.001) and dose-dependent hypolocomotion as shown in Fig. 4C with p values of 0.027, 0.009, and 0.000 at doses of 0.3 g/kg, 1 g/kg, and 10 g/kg, respectively, compared with the control. Even at 0.3 g/kg dose the total movement counts decreased to 1155 Ϯ 248 compared with that of the control mice (2109 Ϯ 264). In addition, the onset of response decreased in a dose-dependent manner immediately after injection and lasted for an hour (Fig.  4D ). There was no significant time effect within the same dose for the whole experimental duration. This was similar to the results obtained from intraperitoneal injection but at extremely low doses. The IC 50 (dose needed to reach ϳ50% inhibition of the locomotion counts) values for intraperitoneal and i.c.v. injections were 3.25 mg/kg and 0.5 g/kg, respectively. Thus ohanin exhibits high potency in inducing hypolocomotion at ϳ6,500-times lower doses when injected through the i.c.v. route, suggesting a central nervous system pathway in the observed effect on locomotion.
Hot Plate Assay-Nociception caused by thermal pain stimulus to the ohanin-administered mice was assessed using the hot plate assay. The dosages used in hot plate assay were the same as those used for the locomotor activity. The effect of ohanin on pain stimulus was evaluated 15 min after intraperitoneal and i.c.v. injections. As shown in Fig. 5, A and B, both the intraperitoneal and i.c.v. injections induced a similar Ushaped dose-response curve. There were no significant effects at all the dosages used when ohanin was injected intraperitoneal (F 3,28 ϭ 0.867, p Ͼ 0.05) (Fig. 5A) . However, it showed a dose-dependent hyperalgesic effect when injected i.c.v. at doses of 0.3 g/kg and 1 g/kg (F 3,50 ϭ 6.390, p Ͻ 0.01). But at higher dose of 10 g/kg, there was no significant hyperalgesic effect. The latency time was statistically significant between 1 g/kg and the control (p ϭ 0.002); between 1 g/kg and 10 g/kg (p ϭ 0.015) as shown in Fig. 5B .
Design, Assembly, and Cloning of the Synthetic Gene-Because the natural abundance of ohanin is low in the crude venom, a synthetic gene that encodes for ohanin based on its protein sequence was constructed by recursive PCR method (22) . The E. coli expression system was selected as ohanin does not contain any post-translational modifications such as glycosylation or disulfide bridges. Second, overexpression of ohanin in E. coli expression system has the advantage of providing adequate amount of recombinant protein to facilitate our future studies on its structure-function relationships.
The overall strategy for synthetic gene design and construction are shown in Fig. 6 (see also "Discussion" for details). Fig. 6A shows the synthetic gene construct for the expression in vectorM. Fig. 6B shows the reverse-translated DNA sequence of the full-length synthetic gene. The strategy for generation of overlapping oligonucleotides in order to obtain the 369 bp synthetic gene is shown in Fig. 6C . Two pairs of oligonucleotides were used to assemble the two fragments (P1 and P2). These two fragments were then ligated via the XmaI site to generate the entire gene. PCR reaction for the extension of overlapping oligos to generate fragments 1 and 2 was performed using the two pairs of oligonucleotides (Fig. 6D) . Ligation of the fragments via XmaI restriction site yielded the full-length synthetic gene of 369 bp (Fig. 6E) . The synthetic gene was cloned into the pGEMT-easy vector and sequenced on both strands with T7 and SP6 primers before subcloning into the expression vector.
Expression of Recombinant Ohanin-E. coli harboring vectorM/ohanin construct was used for the expression of recombinant ohanin. SDS-PAGE analysis of total protein extracted from bacterial culture after overnight induction using 0.1 mM IPTG at 16°C demonstrated an abundant protein of apparent molecular mass of ϳ14 kDa. Comparison of total proteins extracted from uninduced and induced cultures together with fractionation of fusion protein into soluble and insoluble proteins are shown in Fig. 7A . An intense band of 14 kDa (labeled as 1) corresponding to fusion protein appeared in the insoluble fraction. No significant differences in expression of the recombinant protein were observed on changing various parameters, such as expression vectors, bacterial strains, cell density in the culture, incubation temperature, and the amount of IPTG used (data not shown).
Purification and Cleavage of Fusion Protein-The His tag in the fusion protein allowed for rapid purification using a single affinity column under denatured condition. The purification steps are shown in Fig. 7B . Lane 3 showed one major species (ϳ14 kDa), and lane 5 shows the fusion protein with an appar- ent molecular mass of 14 kDa after refolding. The additional 2 kDa of the recombinant protein as compared with the native one corresponds to the N-terminal His tag, thrombin, and CNBr cleavage sites (Fig. 6A) . From 1 liter of bacterial culture, 25 mg of His-tagged fusion protein was purified using Ni-NTA affinity chromatography. CNBr was used to cleave the His tag from the recombinant protein (Fig. 7C) . After cleavage, the recombinant ohanin was purified using RP-HPLC (data not shown), and molecular mass and homogeneity of the protein were determined by ESI/MS. The recombinant ohanin was homogenous, with a molecular mass of 12,022.26 Ϯ 1.42 Da as assessed by ESI/MS (data not shown). The identity of the recombinant protein was further confirmed using N-terminal sequencing by Edman degradation. The N-terminal sequence of the recombinant ohanin was ASPPG, which corresponds to the N-terminal of the native protein except for the alanine that was inserted to improve the efficiency of CNBr cleavage.
Characterization of Recombinant Ohanin-The secondary structures of the native and recombinant protein were evaluated by CD spectroscopy analysis (Fig. 8) . The CD spectrum of the native protein showed negative ellipticity extrema near 200 Thrombin and CNBr cleavage sites are indicated as Tb and CNBr, respectively. The DNA fragment between the two arrows was inserted into vectorM at the BamHI and NotI sites. B, full-length sequence of the synthetic gene. Amino acid sequence is shown below the DNA sequence. Ten unique restriction sites (AatII, BstBI, AclI, XhoI, AvrII, XmaI, BspEI, KpnI, NheI, and AflII) are in bold. C, strategy for construction of the synthetic gene. Two pairs of oligonucleotides, ranging from 96 to 117 bp in length, were used to assemble the two fragments (P1 and P2). These two fragments were then ligated via XmaI site to generate the entire gene (see "Experimental Procedures" for details). D, agarose gel (1.5%, w/v) electrophoresis of the two fragments; E, the synthetic gene. and 215 nm, indicating a ␤-sheet and random coil structures with more of ␤-sheet conformation. The CD spectrum of the recombinant protein is similar to that of the native protein with negative ellipticity values at 200 and 215 nm. The constitutions of the secondary structures calculated from the CD spectra are shown in Fig. 8B .
To test whether recombinant ohanin has similar pharmacological actions as the native protein, we studied its hyperalgesic effect in i.c.v.-administered mice. The recombinant ohanin exhibited the U-shaped dose-response curve similar to that of the native protein (F 3,45 ϭ 5.783, p Ͻ 0.01) (Fig. 5, B and C) . Significant differences were found between 1 g/kg dose and the control; and between 1 g/kg and 10 g/kg dose with p values of 0.007 and 0.015, respectively. These results indicate that the recombinant ohanin is structurally and functionally similar to the native protein isolated from the venom. DISCUSSION We identified the presence of a novel protein with an unusual molecular mass using initial screening of king cobra venom by LC/MS (Fig. 1) . Here we describe the purification and characterization of this protein, ohanin. The complete amino acid sequence of ohanin was determined by Edman degradation. It has 107 amino acid residues with a single cysteine residue (Fig.  3) . It does not have similarity to any of the well established families of snake venom proteins. Thus ohanin and Thai cobrin (isoform reported from Thai cobra) are the first members of a new family of snake venom proteins. The unique feature of the members of this family appears to be the low content of cysteine residues (Ͻ1%). In contrast, the members of all the other snake venom protein families have multiple disulfide bonds and high contents of cysteine residues (generally more than 8 -10%).
Ohanin and B30.2-like Domain Proteins-CDD search revealed that ohanin shares similarity with the PRY-SPRY domains (Fig. 3B) . Three copies of SPRY domains were first identified in three mammalian ryanodine receptor (RyR) subtypes. This domain is also present in three copies in a dualspecificity kinase, splA, found in Dictyostelium discoideum. Because of the repeats in splA and RyR, these sequences are therefore referred to as SPRY domain (23) . The SPRY domain has been identified as a subdomain within the B30.2-like domain family (19) . The SPRY domain, when compared with the B30.2-like domain, has a deletion at the N-terminal region. It is interesting to note that the PRY domain, which comprises of ϳ50 residues, has always been found at the N-terminal region of SPRY domain (ϳ110 -120 residues). Hence, both PRY-SPRY domains could be regarded as subdomains of the B30.2-like domains.
The B30.2 domain is a conserved protein domain of around 160 -170 amino acids which is encoded by a single exon, mapping within the Human Class I Histocompatibility Complex (MHC) region (24) . It was, therefore, named after the B30.2 exon in the MHC I region in which it was originally identified. The B30.2-like domain occurs in nuclear, cytoplasmic, transmembrane, or secreted proteins, particularly at the C-terminal regions and these proteins are classified according to the type and/or the function of N-terminal domains (20, 21) domain proteins are found in diverse species and in different protein contexts, the function(s) of the B30.2-like domain is not clearly understood yet (20, 21) . Based on the structural similarity, we include ohanin as a new member of the rapidly expanding B30.2-like domain family. However, it appears to be unrelated to any of the other classes of proteins containing the B30.2-like domains. It is interesting to note that ohanin has a relatively short N-terminal region of only 8 amino acid residues as compared with that of other proteins containing B30.2-like domains (Fig. 3B) . In addition, ohanin also has a shorter Cterminal region, lacking the 50 -60 amino acid residues at the C-terminal region of the B30.2-like domain. Similar C-terminal truncation in the B30.2-like domain is also found in KIAA0129 isolated from human cell line KG-1 (GB: D50919) and Staf50 (GB: X82200) (Fig. 3B) .
Biological Function(s) of Ohanin-Ohanin induces hypolocomotion in experimental mice by intraperitoneal injection in a dose-dependent manner (Fig. 4) . It should be noted that neurotoxins in snake venoms are particularly important in inducing paralysis of skeletal muscles (25) . To test whether ohanin induces blocking of peripheral neuromuscular junction, we studied its effect on isolated chick biventer cervicis nervemuscle preparations (CBCNM). Ohanin possesses no effect on the direct twitch response of the CBCNM stimulation as well as on the responses to exogenously applied agonists, such as ACh, CCh, and KCl. 2 These results indicate that ohanin is devoid of both presynaptic and postsynaptic toxicity (including myotoxicity). Therefore, we directly injected ohanin into the ventricles of the mice to examine its pharmacological actions in the central nervous system. Ohanin produced ϳ6,500-times more potent hypolocomotion activities when injected i.c.v. compared with intraperitoneal injections. Thus, ohanin induces hypolocomotion that is presumably mediated by a direct action on the central nervous system. Further studies are underway to determine whether ohanin crosses the blood-brain barrier.
In hot plate assay, both the intraperitoneal and i.c.v. injection routes induced a similar U-shaped dose-response curve (Fig. 5, A and B) . Although lower and intermediate doses showed shorter average latency times, there were no obvious differences in the latency time between the high doses and the respective controls. The results suggest that the effects of locomotor impairment caused by ohanin need to be considered when interpreting the results from hot plate assay, which is dependent on a normal functioning motor system. The increase in the latency time at higher doses of ohanin administered may have been caused by severe impairment in the movements. Therefore, the mice would not be able to respond immediately to the thermal pain experienced. Again, the ability of the protein to elicit a response at greatly reduced doses for i.c.v. injection as compared with systemic administration in the hot plate assay strongly suggests that ohanin probably has a direct effect in the central nervous system. However, the exact mode of action of ohanin is yet to be investigated.
Butyrophilin is involved in the budding and release of milkfat globules during lactation (24, 26) . Its B30.2-like domain interacts with xanthine dehydrogenase/oxidase and this interaction appears to be important for its function (26, 27) . Based on the assumption that proteins containing similar domains exert their functions through similar protein-protein interaction and mechanisms, Henry et al. (20, 21) proposed a mechanism for the hypotensive action of SNTX that is mediated through the release of endothelium-derived relaxing factor (probably NO or NO-yielding substances). Accordingly, SNTX through its B30.2-like domain would interact with xanthine oxidase relieving the xanthine oxidase-mediated inhibition of NO synthase. This in turn would lead to increased synthesis of NO and vasorelaxation (20, 21, 28, 29) . In our study, ohanin did not exhibit any significant effect on the blood pressure in anesthetized Sprague-Dawley rats up to the dose of 1 mg/kg when given intravenously. 3 Although we have not examined the direct interaction of ohanin with xanthine oxidase, we propose that ohanin function is independent of xanthine oxidase.
Design of the Synthetic Gene and Cloning of Ohanin-We are interested in the study of structure-function relationships of small and novel venom proteins from snakes (7). For these studies, which lead to the use of venom proteins as models for drug design and antivenoms, a reliable and inexpensive method for obtaining the proteins is needed. One potential method for obtaining the proteins is to produce them using solid-phase peptide synthesis and combinatorial chemistry. A second, less expensive method is to overexpress the protein in bacterial hosts using molecular biology techniques. Synthetic gene for the production of proteins is a powerful approach. In this approach, either single amino acid or entire protein domain changes can be easily achieved as compared with the cDNA sequence (30) .
The synthetic gene was designed as follows: first, the amino acid sequence of ohanin was reverse-translated into nucleotide sequence through the use of the triplet codons that occur most frequently in E. coli (31) . Second, a total of six common restriction sites were added at the 5Ј-and 3Ј-region of the synthetic gene for easy subcloning into a wide range of expression vectors. Third, 10 unique restriction sites were introduced, without changing the encoded amino acid sequence, into the sequence for future cassette-based mutagenesis. The goal was to produce a nucleotide sequence, which contained restriction sites that for a variety of restriction enzymes would cleave the gene only once. In addition, the restriction sites flanked conserved sequence motifs of B30.2-like domain and cysteine residue of the gene, and were present approximately every 20 -45 bp. Such a construction would permit the easy manipulation of the encoded amino acid sequence by digestion with two restriction endonucleases, removal and ligation of the replacement DNA segment. Fourth, codons for Met-Ala residues were incorporated at the N-terminal of ohanin to facilitate CNBr cleavage from the fusion protein after expression as ohanin does not contain any Met residue in its amino acid sequence. Fifth, a stop codon was introduced after the last amino acid residue to stop the translation process. Finally, the sequence was checked by various computer programs such as DNAman and DNAsis followed by visual inspection for undesired restriction sites and potential for excess secondary structures (Fig. 6B) . Using this synthetic gene, we produced the recombinant ohanin in E. coli. The recombinant ohanin resembles the native protein in its folding and function as determined by CD (Fig. 8 ) and biological activity (Fig. 5C ). Thus the designed synthetic gene will be important for future study on the structure-function relationships of this novel protein.
Physiological Role(s) of Ohanin-Snake venom is a complex mixture of pharmacologically active peptides and proteins. They play important role in both offensive and defensive functions. Some of these proteins, such as neurotoxins, are involved in paralyzing the prey, while others including hydrolytic enzymes may be involved in digesting the prey animals. We propose that ohanin could contribute by slowing down the mobility of the prey and helping in its capture. The hyperalge-sic effect may also help in the defensive function by inducing pain in predatory animals. We have not observed ohanin-associated protein complexes in the venom. Further studies are needed to clarify the role played by ohanin in relation to other components present in the venom. CONCLUSION We have identified, purified, and functionally characterized a novel protein, ohanin from king cobra venom. Ohanin induces hypolocomotion and hyperalgesia in mice. The effectiveness of ohanin administered by i.c.v. route as compared with systemic administration strongly suggests its action through the central nervous system although the role of peripheral nervous system cannot be ruled out. We have also established a synthetic gene expression system for its future structure and function relationship studies. The detailed mechanism of action(s) of ohanin at the molecular level is currently under investigation.
